阿托伐他汀联合曲美他嗪治疗冠心病的临床效果及对患者血清炎性因子水平的影响

Clinical effect of atorvastatin combined with trimetazidine in the treatment of coronary heart disease and its effect on serum inflammatory factors of patients

目的研究阿托伐他汀联合曲美他嗪治疗冠心病的临床效果及其对患者血清炎性因子水平的影响。方法将收治的92例冠心病患者根据治疗方式分为对照组与联合方案组,每组46例。对照组采用曲美他嗪治疗,联合方案组则给予阿托伐他汀联合曲美他嗪治疗。比较两组患者的治疗效果。结果治疗后,联合方案组患者ST段下移1 mm时间、平板运动时间、左心射血分数均明显优于对照组与治疗前(P<0.05)。联合方案组的治疗总有效率明显高于对照组(P<0.05)。治疗后,两组的血清炎性因子水平明显低于治疗前,且联合方案组明显低于对照组(P<0.05)。两组不良反应总发生率比较,无显著差异(χ~2=0.541,P=0.489)。结论阿托伐他汀联合曲美他嗪治疗冠心病的临床效果确切,安全性高,值得推广应用。

Objective To study the clinical effect of atorvastatin combi ned with trimetazidine in the treatment of coronary heart disease and its effect on serum inflammatory factors of patients. Methods A total of 92 patients with coronary heart disease in our hospital were selected and divided into control group and joint programme group according to the treatment methods, with 46 cases in each group. The control group was treated with trimetazidine, and the joint programme group was treated with atorvastatin combined with trimetazidine. The treatment effects in both groups were compared. Results After treatment, the time of ST segment depression 1 mm, flat motion time and left ventricular ejection fraction in the joint programme group were better than those in the control group and before treatment（P〈0.05）. The total treatment efficiency of the joint programme group was significantly higher than that of the control group（P〈0.05）. After treatment, the levels of serum inflammatory factors in two groups decleased, and those in the joint programme group were lower than the control group（P〈0.05）. There was no significant difference in the total incidences of adverse reactions between the two groups（P〈0.05）. Conclusion Atorvastatin combined with trimetazidine in the treatment of coronary heart disease has significant effect, with high safety, which is worthy of popularization and application.